Bioeconomy in India — Size, Sub-sectors, BioE3 Policy, Targets (UPSC Science & Tech)

India's bioeconomy crossed $150 billion in 2023 — more than double the 2020 figure — and the BioE3 (Biotechnology for Economy, Environment, Employment) Policy approved by the Union Cabinet in August 2024 sets a $300 billion target by 2030. The country went from ~2% of global biotech revenue a decade ago to ~4% today. For UPSC GS III, bioeconomy is a recurring theme under science and technology, indigenisation, economy and health.

What is the Bioeconomy

Bioeconomy refers to all economic activities generated from biological resources and processes — biotechnology, biomanufacturing, bio-services and bio-based products. It spans everything from vaccines and biofuels to gene therapy and bio-pesticides.

Size and Targets

• 2023-24: ~$150 billion (per India BioEconomy Report 2024 by BIRAC).
• Target 2025: $150B (achieved early).
• Target 2030: $300 billion (per BioE3 Policy).
• Global share: ~4%; aim 6-8% by 2030.
• Number of biotech start-ups: 10,000+ (2024), up from 50 in 2014.
• Top 12 global biotech destinations — India is one.

Five Sub-sectors of Bioeconomy

1. Biopharma — 64% of Indian bioeconomy

• Diagnostics — Molecular kits for TB, malaria, typhoid, filariasis, hepatitis.
• Therapeutics — Biosimilars, biologics, monoclonal antibodies.
• Vaccines — India is the world's largest vaccine producer by volume. Serum Institute of India (SII), Bharat Biotech, Biological E supply to 150+ countries. Vaccine Maitri programme during COVID.
• Hepatitis B R-DNA vaccine — First Indian recombinant DNA product.
• 16+ WHO prequalified vaccines including rotavirus, pneumococcal, COVID-19.
• Generic drug export — India supplies 40% of US generic demand.

2. Bio-agriculture

• Bt cotton — 93%+ of India's cotton is Bt (since 2002).
• Biofortified crops — Iron-rich pearl millet, zinc wheat, vitamin-A rice.
• Biopesticides and biofertilisers — Trichoderma, Rhizobium, Azotobacter.
• Gene editing (CRISPR) — India cleared SDN1/SDN2 genome-edited crops in 2022 exempting them from GMO regulation.
• Nano urea / nano DAP from IFFCO.
• Marker-assisted selection for drought, pest resistance.

3. Bio-industry

• Biofuels — Ethanol blending from sugarcane and agricultural waste; 12%+ blending achieved 2023-24.
• Biodegradable bioplastics.
• Industrial enzymes for textiles, paper, laundry.
• Fermentation-derived chemicals replacing petrochemicals.
• Bio-based polymers and bio-silk.

4. Bio-services

• Contract research organisations (CROs).
• Clinical trials.
• Contract manufacturing organisations (CMOs).
• India's share in global clinical trials < 2%; BioE3 aims to raise it.

5. Bio-informatics

• Genomics, proteomics, metabolomics, transcriptomics.
• Indian Biological Data Centre (IBDC), Faridabad — Open-access repository for life sciences data.
• IndiGen — 1,000-genome sequencing programme (CSIR).
• Genome India Project (GIP) — 10,000 Indian genome sequencing (DBT, 2020-24).
• Indian Human Atlas Project — Cell-level atlas.
• Supercomputing — C-DAC's Param Biochrome, Param BioBlaze.

BioE3 Policy 2024

Approved by Union Cabinet in August 2024, the BioE3 Policy (Biotechnology for Economy, Environment and Employment) is the flagship framework.

Key Themes

• High-performance biomanufacturing — From bio-based chemicals to engineered enzymes.
• Bio-AI hubs, biofoundries — Industrial bioscience infrastructure.
• Regenerative bioeconomy — Climate-smart crops, precision fermentation.
• Job creation — Target: millions of new biotech jobs by 2030.
• Bio-pharmaceuticals — Indigenous mRNA, viral vector, cell and gene therapy platforms.
• Biotech start-up support — New schemes under BIRAC.

Six Priority Areas

• Bio-based chemicals and enzymes.
• Smart proteins / functional foods.
• Precision biotherapeutics.
• Climate-resilient agriculture.
• Marine and space research biotech.
• Carbon capture and utilisation via microbes.

Institutional Framework

• Department of Biotechnology (DBT) — Nodal ministry since 1986.
• Biotechnology Industry Research Assistance Council (BIRAC) — Enables industry-academia partnerships.
• ICGEB (International Centre for Genetic Engineering and Biotechnology) — Global R&D hub in Delhi.
• NIBMG (National Institute of Biomedical Genomics), Kalyani — Genomics research.
• CSIR-IGIB, CCMB, IMTech — Research institutes.
• Genome Valley, Hyderabad — Biotech industrial cluster.

Challenges

• R&D spending — Still ~0.7% of GDP, well below US (3.5%) and China (2.4%).
• Regulatory complexity — GEAC, CDSCO, FSSAI, DCGI overlap.
• Intellectual property gaps — Indian firms rarely originate new drug molecules.
• Skill shortage — Specialised bio-manufacturing talent.
• Funding for start-ups — Series B/C capital thin.
• Ethical issues — Gene editing, clinical trial standards.
• Biosafety — Lab accidents, dual-use research concerns.

Benefits

• Jobs — 5-7 million new jobs by 2030 (BioE3 projection).
• Health security — Atmanirbhar in vaccines and biologics.
• Food security — Climate-resilient crops.
• Energy transition — Biofuels, biogas.
• Exports — Generics, vaccines, services to 150+ countries.
• Green economy — Bio-based alternatives to petrochemicals.

Latest Developments (2024-26)

• BioE3 Policy approval (Aug 2024) — Cabinet-approved.
• $300 billion by 2030 target formalised.
• Indigenous mRNA vaccine platform operationalised at Gennova and Bharat Biotech.
• Nexcar19 (ImmunoACT IIT Bombay) — India's first indigenous CAR-T therapy approved 2023.
• CRISPR therapy trials — Sickle cell anaemia gene therapy trials.
• India Semiconductor Mission — Biosensor chipsets on DLI priority list.
• National Quantum Mission (2023) — Quantum biosensors under development.
• AI policy (IndiaAI Mission, 2024) — AI for drug discovery, protein structure prediction.
• Chandrayaan-4 payload — Space biology experiments planned.
• Gaganyaan bio-experiments — Microbiome studies in microgravity.
• DPDP Act 2023 — Genetic and health data handling under new rules.
• Ethanol blending 12%+ achieved — 20% target by 2025.
• IndiGen Phase-II — Expanded Indian genome sequencing.
• Biobank expansion — IBDC scaled up.

UPSC Relevance

Prelims angles

• Bioeconomy size: ~$150 billion (2023-24).
• BioE3 Policy — approved August 2024.
• Target $300 billion by 2030.
• Five sub-sectors: biopharma, bio-agriculture, bio-industry, bio-services, bio-informatics.
• Nodal ministry: DBT.
• BIRAC, IBDC Faridabad, Genome India Project.

Mains angles

• GS III — Science and technology: "Analyse the BioE3 Policy as India's pathway to a $300 billion bioeconomy."
• GS III — Economy: "Bioeconomy as a sunrise sector — potential and constraints."
• GS III — Health: "India's biopharma leadership and its contribution to global health security."

Essay angles

• "Biology is destiny — and industry."
• "From pharmacy of the world to biotech superpower."

Practice question — "The BioE3 Policy is ambitious but depends on execution. Critically examine."

Biology is to the 21st century what chemistry was to the 20th. India has chosen not just to participate but to lead — and the BioE3 framework is the most coherent bet the government has placed on that proposition.

PDF